There’s a famous quote by Friedrich Nietzsche that says “That which does not kill us makes us stronger.” I have follicular ...

Follicular lymphoma is a very diverse disease, and decisions to treat in the frontline are made based on histology, disease burden and patient symptoms. The general approach should be a ...

Christopher R. Flowers, MD, MS, discusses what the current treatment landscape of follicular lymphoma looks like.

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

Monjuvi is available under an accelerated approval to treat adults with relapsed or refractory diffuse large B-cell lymphoma.

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer based on its unique Mimicry platform, will be holding a webinar to run through new clinical data from the ...

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has reported promising results from its Phase Ib/IIa clinical trial of IMM0306, a bispecific molecule for treating indolent lymphoma. The trial ...

These presentations will disclose the first data from Phase 2 Cohort 2, evaluating EO2463 as monotherapy for newly diagnosed patients with asymptomatic follicular lymphoma, where EO2463 may offer a ...

Santa Monica, California Thursday, November 7, 2024, 10:00 Hrs [IST] ...